Navigation Links
Neurologix Announces First Quarter 2011 Financial Results
Date:5/13/2011

ble future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At March 31, 2011, the Company had cash and cash equivalents of approximately $5.4 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan of operations after October 31, 2011 and to repay the promissory notes issued in 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Neurologix Completes Additional $7 Million Financing
    5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 23, 2014 Echo Therapeutics, ... device company focused on skin permeation, continuous glucose ... Scott W. Hollander has been appointed Chief ... has more than 20 years of experience in ... and most recently served as Vice President, Business ...
    (Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
    (Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
    Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
    ... 11, 2011 Amarin Corporation plc (Nasdaq: AMRN ... on cardiovascular disease, today announced that it has completed its ... at a price to the public of $7.60 per ADS. ... underwriters, over-allotment option, the company sold a total of 13,800,000 ...
    ... CITY, Mo., Jan. 11, 2011 Clients ... Health Solutions, LLC, now have access to a customizable, ... drug claims. Medical Drug Management Service™ (MDMS) is a ... trend management, assist with appropriate and consistent patient care ...
    Cached Medicine Technology:Amarin Announces Successful Completion of Offering of American Depositary Shares 2Amarin Announces Successful Completion of Offering of American Depositary Shares 3DST HealthCare Launches Medical Drug Management Service™ 2DST HealthCare Launches Medical Drug Management Service™ 3
    (Date:12/25/2014)... SmileStix ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Andrew Tropeano, a ... review and shared with viewers how this is an application ... goes, “A picture says a thousand words.” It’s true. There ... image, because each picture holds a unique and special meaning. ...
    (Date:12/25/2014)... 2014 Parker & Sons, Inc. an ... and affordable quality regarding heating, cooling and plumbing services ... 2014 by the “Queen of Clean” for impressive contractor ... impressive reputation over the years for providing outstanding quality ... of contractor services for both homeowners and businesses. Linda ...
    (Date:12/24/2014)... December 24, 2014 Connie Casad, MD, ... functional medicine advocate with 30 years of practice experience ... evaluate the health benefits of dietary detoxification. The second ... participants following excellent results from test patients who just ... to explain her interest in conducting the study, Dr. ...
    (Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
    (Date:12/24/2014)... 25, 2014 The report “Stivarga (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is a drug which is used in the treatment ... administered and is also prescribed to patients who suffer ... FDA approved is a multi-kinase inhibitor and it blocks ...
    Breaking Medicine News(10 mins):Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
    ... a trend setter of sorts. Now, BT Offices and Vans ... that smoking is banned in the BT premises as well ... Importantly, this move might encourage “anti-smoking” initiatives in other industries ... announcement, which will surely set a precedent. Now this means ...
    ... revealed that although cardiologists are well informed about the possibility ... consequence of eating vegetarian diet, they fail to recommend patients ... // ,With this on one side, studies ... show that they are more than willing to adapt the ...
    ... to tackle any Bird Flu cases. A 10-bedded ward has ... and another 20// bedded ward has been set up at ... patients with avian influenza or bird flu., ,Another step ... food restaurant in the city to obtain chickens from only ...
    ... than famous, is now going to face some competition. Private ... Canada, having garnered enough support from the several provinces in ... the Quebec government, which intended to remove the ban on ... offered to chip in and pick up costs for such ...
    ... or blame all those people who had been telling you ... part for bone strength but is not the only one.,It ... ,As per a recent study which is part of Woman's ... D supplements may not be effective in preventing osteoporosis in ...
    ... are thrice as likely to miscarry during the first three ... // The study is the first of it’s kind to ... pregnancy loss at an early stage. ,Cortisol is ... levels of this hormone serve as a reliable stress indicator. ...
    Cached Medicine News:Health News:Calcium in isolation no good for maintaining bone integrity 2Health News:Early Miscarriage Common In Women Under Stress 2
    VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
    Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
    BD Vacutainer® Fluoride Tubes - Plastic...
    VACUETTE Trace Element tubes - Non-ridged (pull cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
    Medicine Products: